Cureus

Review began 02/07/2022 Review ended 02/13/2022 Published 02/22/2022

#### © Copyright 2022

Daines et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

# Seizures Related to Neurocysticercosis and Cocaine Use

Benjamin S. Daines $^1$ , Katherine G. Holder $^1$ , Balaji Mohanakrishnan $^1$ , James W. Walker $^1$ 

1. Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, USA

Corresponding author: Benjamin S. Daines, benjamin.daines@ttuhsc.edu

#### Abstract

Neurocysticercosis (NCC) is an infection of the central nervous system with *Taenia solium* cysts that most commonly results in seizures. In stable patients without recent symptoms, these seizures may be provoked by seizure threshold-lowering drugs such as cocaine. This case details a 38-year-old male with a past medical history of epilepsy presenting with seizures due to comorbid NCC and cocaine use. This case was complicated by the lack of available information regarding the patient's past medical history and medication use. We highlight the importance of obtaining a full work-up, including brain imaging, to provide optimal treatment for patients with seizures despite a history of drug use.

Categories: Internal Medicine, Infectious Disease, Substance Use and Addiction Keywords: drug-induced seizure, taenia solium, infectious and parasitic diseases, seizure, cocaine use, neurocysticercosis

### Introduction

Neurocysticercosis (NCC) is the most common helminthic central nervous system infection in humans and is a common cause of epilepsy throughout South America [1,2]. While NCC is a rare diagnosis in the United States with an estimated incidence of 0.2 to 0.6 cases per 100,000, it disproportionately impacts Hispanic populations in the United States with an incidence up to 5.8 cases per 100,000 [3]. With a growing Hispanic community in the United States, NCC has become an increasingly important clinical consideration due to significant associated morbidity via seizures, hydrocephalus, and cerebral edema [4]. Early recognition and treatment of NCC with cysticidal drug therapy can reduce recurrence of seizures and aid in resolution of parenchymal cysts [5].

Cocaine use can also result in seizures or exacerbate an underlying seizure disorder by lowering the seizure threshold due to indirect sympathomimetic effects [6]. Patients in the emergency department who had used cocaine presented due to seizures in nearly 10% of cases [7]. While cases of cocaine-induced seizures have decreased, cocaine use is still an important consideration in a patient presenting with seizures [8]. Currently, there are no peer-reviewed cases in the literature describing comorbid NCC and cocaine use. Here, we present a case of a 38-year-old male with seizures due to NCC and cocaine use.

### **Case Presentation**

A 38-year-old male with a past medical history of epilepsy presented after two episodes of seizures 3 hours apart on the day of presentation. The seizures were witnessed by family. Each episode lasted approximately 5 minutes and resulted in loss of consciousness with post-ictal confusion. The patient denied nausea, vomiting, bowel changes, chest pain, shortness of breath, paresthesia, weakness, vision changes, and headache. He endorsed some fatigue. The patient was asleep prior to the episodes and had no recent changes in physical activity, eating, drinking, or stressful inciting events. He denied recent sick contacts and travel. He endorsed drinking alcohol 1-2 times weekly but denied tobacco and recreational drug use. One year ago, the patient moved to the United States from Mexico where he had lived his entire life. He stopped taking his seizure medication for epilepsy one year ago. He does not know what seizure medication he was taking nor any details of his epilepsy diagnosis from childhood. He says he has not had a seizure since he was a child. He endorsed no family history of epilepsy or other medical conditions.

On physical examination, there were no focal neurological deficits. Cranial nerves II through XII were intact with normal sensation and strength in all extremities bilaterally. Deep tendon reflexes were 2+ bilaterally. The patient was alert and oriented to person, place, and time. Vital signs were stable and initial laboratory values in Table 1 revealed mild leukocytosis without eosinophilia. Urine drug screen was positive for cocaine. When this result was brought up, the patient admitted to using cocaine a few times in the past, but not habitually. He said his most recent cocaine use was a few days ago. The previous cocaine use with normal physical examination findings indicated a likely drug-induced seizure, but additional imaging was ordered due to the unknown etiology of the patient's childhood epilepsy diagnosis.

### Cureus

Investigation	Value	Reference Range
WBC (k/µL)	12.8	4.8-10.8
Hemoglobin (g/dL)	14.8	14.0-18.0
Eosinophils (%)	0.5	0.0-5.0
Platelets (k/µL)	251	150-400
Sodium (mmol/L)	140	135-145
Potassium (mmol/L)	4.0	3.5-5.0
Chloride (mmol/L)	109	98-107
Bicarbonate (mmol/L)	20	21-31
ALP (U/L)	67	25-100
ALT (U/L)	40	10-40
AST (U/L)	31	12-38

#### **TABLE 1: Laboratory Results**

WBC: white blood cells; ALP: alkaline phosphatase; ALT: alanine transaminase; AST: aspartate transaminase

Brain MRI demonstrated a non-enhancing T1 hyperintense 1.7 cm diameter lesion (Figure 1) within a larger cystic 2.6 cm diameter lesion in the atrium of the right lateral ventricle adherent to the choroid (Figure 2). There was asymmetric enlargement of the right ventricle. These MRI findings combined with the previous diagnosis of epilepsy and social history of growing up in Mexico indicated a clinical diagnosis of NCC. The patient was subsequently started on lorazepam 2 mg IV as needed and levetiracetam 500 mg IV every 12 hours while inpatient for seizure prevention. Neurosurgery determined surgical intervention was unnecessary at the time and requested a follow-up MRI in six months to determine cyst stability. Infectious disease recommended a 14-day and 21-day course of albendazole and dexamethasone, respectively, with neurology follow-up for seizure control. The patient appeared clinically well with no new seizures or neurological changes at 24 hours, so they were discharged on albendazole 600 mg twice a day for 14 days, dexamethasone 2 mg three times a day for 21 days, and levetiracetam 500 mg twice a day until neurology follow-up. The patient was advised to stop recreational drug use to help prevent seizure recurrence. Follow-up imaging and neurology appointments were scheduled.




FIGURE 1: Sagittal T1-weighted brain MRI demonstrating non-enhancing hyperintense lesion.




FIGURE 2: Axial T1-weighted brain MRI demonstrating hyperintense lesion within larger cystic lesion and enlargement of the right ventricle.

### **Discussion**

NCC is a common cause of seizures worldwide and occurs due to ingestion of eggs from the cestode *Taenia solium* [1]. These eggs are transmitted fecal-orally from a human carrier of the tapeworm [1]. *T. solium* is responsible for both cysticercosis via ingestion of eggs and taeniasis, a mild gastrointestinal infection via ingestion of cysts from undercooked pork [1]. NCC is cysticercosis that develops in the central nervous system. The variety in number, size, stage, and location of cysts along with differences in host immune response results in varied pathophysiologic effects [9]. While vestibular cysticerci tend to result in little inflammation, colloidal and meningeal cysticerci can cause intense inflammatory responses resulting in gliosis and edema [9]. The chronic nature of NCC due to the persistence of cysts for years along with a varied disease progression makes diagnosis a significant challenge [9].

Symptomatic NCC most commonly presents with seizures, but many will present with hydrocephalus, focal neurologic deficits, or headache [10]. Diagnosis may be a challenge due to non-specific presentation coupled with difficulty in obtaining a biopsy specimen for histopathologic analysis [9]. Initial diagnosis begins with neuroimaging via CT and MRI [9]. Visualization of several cysts displaying "hole-with-dot" patterns indicative of the tapeworm scolex can confirm a diagnosis of NCC [9,11]. Locating such an image for diagnosis is often unattainable due to variability in stage of cyst involution [9]. Cysticerci often appear as non-enhancing hyperdense lesions [9]. MRI with fluid-attenuated inversion recovery tends to better visualize intraventricular cysts, such as in this case [11]. Gold standard for diagnosis with 98% sensitivity and 100% specificity is an enzyme-linked immunoelectrotransfer blot (EITB) for *T. solium* antibodies in serum [12].

While EITB was not obtained in this case, a clinical diagnosis could be made with characteristic imaging

findings alongside the patient's social history. Epidemiologic factors play a critical role in the diagnosis of NCC. NCC is endemic to South America, parts of Central America, and Asia [3]. NCC rates in autopsies from these countries are as high as 3.6% [9]. In Mexico, records from a large neurologic hospital found an NCC rate of 2.5% [13]. With changes in immigration patterns, 90% of NCC diagnoses in the United States and Europe are Central American immigrants [3]. In this case, the patient was an immigrant from Mexico with epilepsy of unknown origin, so NCC was an important consideration. Diagnosis should be supplemented by history of immigration from endemic areas or contacts with known carriers of *T. solium*.

No previous literature has linked NCC-induced seizures to cocaine use. While the patient in this case endorsed a lack of seizures since childhood with and without their anti-seizure medication, the recent cocaine use likely contributed to the new-onset seizures. Cocaine can lower the seizure threshold via indirect sympathomimetic effects [6]. While most cocaine-induced seizures appear to occur within hours of use, cocaine metabolites can persist for days before clearance [14,15]. This persistent adrenergic hyperactivity may lower the seizure threshold for an extended period. Previous studies investigating the effects of cocaine use on grey and white matter have shown inconsistent results and cocaine appears to have no significant impact on overall brain structure [16]. Further investigation is necessary to determine the impact of cocaine and brain masses like NCC on provocation of seizures.

Typical treatment of NCC typically consists of cysticidal drug therapy, anti-seizure medication, and antiinflammatories. Albendazole (15 mg/kg/day) has been identified as the superior cysticidal therapy for reducing the burden of cystic brain lesions due to NCC [17]. Praziquantel (50 mg/kg/day) is another available therapy, albeit a less efficacious option for reducing cysts [17]. For seizure prevention, a first-line antiepileptic, such as levetiracetam in this case, is adequate [3]. The length of anti-epileptic treatment is a continuing matter of debate with a previous study finding 50% of patients with successfully treated brain cysticerci experiencing seizures after withdrawal of anti-epileptics [18]. The patient in this case was discharged on levetiracetam to be adjusted at the discretion of his neurologist. Anti-inflammatories, such as steroids, have shown efficacy in reducing seizures due to cyst degeneration via albendazole or praziquantel [19]. In this case, dexamethasone (0.1 mg/kg/day) was used for the duration of cysticidal therapy to successfully prevent seizures.

### Conclusions

This patient presented with a seizure and evidence of comorbid NCC and cocaine use. While NCC is exceedingly rare in the United States, it should be an important consideration in any patient from an NCC-endemic region presenting with seizures of unknown origin. Despite initial urine drug screen findings, thorough work-up including brain imaging is necessary to appropriately diagnose and treat patients with seizures. Treatment with cysticidal therapy and drug cessation counseling can prevent subsequent seizures and significantly improve patient symptoms.

## **Additional Information**

#### Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

### References

- 1. Del Brutto OH: Neurocysticercosis: a review. ScientificWorldJournal. 2012, 2012:159821. 10.1100/2012/159821
- Medina MT, Durón RM, Martínez L, et al.: Prevalence, incidence, and etiology of epilepsies in rural Honduras: the Salamá Study. Epilepsia. 2005, 46:124-31. 10.1111/j.0013-9580.2005.11704.x
- Serpa JA, White AC Jr: Neurocysticercosis in the United States. Pathog Glob Health. 2012, 106:256-60. 10.1179/2047773212Y.0000000028
- Wallin MT, Kurtzke JF: Neurocysticercosis in the United States: review of an important emerging infection. Neurology. 2004, 63:1559-64. 10.1212/01.wnl.0000142979.98182.ff
- Del Brutto OH, Roos KL, Coffey CS, García HH: Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med. 2006, 145:43-51. 10.7326/0003-4819-145-1-200607040-00009
- Koppel BS, Samkoff L, Daras M: Relation of cocaine use to seizures and epilepsy. Epilepsia. 1996, 37:875-8. 10.1111/j.1528-1157.1996.tb00041.x
- Derlet RW, Albertson TE: Emergency department presentation of cocaine intoxication. Ann Emerg Med. 1989, 18:182-6. 10.1016/s0196-0644(89)80111-8
- Thundiyil JG, Kearney TE, Olson KR: Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System. J Med Toxicol. 2007, 3:15-9. 10.1007/BF03161033
- 9. Pittella JE: Neurocysticercosis. Brain Pathol. 1997, 7:681-93. 10.1111/j.1750-3639.1997.tb01083.x

- 10. Carabin H, Ndimubanzi PC, Budke CM, et al.: Clinical manifestations associated with neurocysticercosis: a systematic review. PLoS Negl Trop Dis. 2011, 5:e1152. 10.1371/journal.pntd.0001152
- 11. Lerner A, Shiroishi MS, Zee CS, Law M, Go JL: Imaging of neurocysticercosis. Neuroimaging Clin N Am. 2012, 22:659-76. 10.1016/j.nic.2012.05.004
- Tsang VC, Brand JA, Boyer AE: An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis. 1989, 159:50-9. 10.1093/infdis/159.1.50
- Fleury A, Moreno García J, Valdez Aguerrebere P, de Sayve Durán M, Becerril Rodríguez P, Larralde C, Sciutto E: Neurocysticercosis, a persisting health problem in Mexico. PLoS Negl Trop Dis. 2010, 4:e805. 10.1371/journal.pntd.0000805
- 14. Pascual-Leone A, Dhuna A, Altafullah I, Anderson DC: Cocaine-induced seizures. Neurology. 1990, 40:404-7. 10.1212/wnl.40.3\_part\_1.404
- Jufer RA, Wstadik A, Walsh SL, Levine BS, Cone EJ: Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. J Anal Toxicol. 2000, 24:467-77. 10.1093/jat/24.7.467
- Narayana PA, Datta S, Tao G, Steinberg JL, Moeller FG: Effect of cocaine on structural changes in brain: MRI volumetry using tensor-based morphometry. Drug Alcohol Depend. 2010, 111:191-9. 10.1016/j.drugalcdep.2010.04.012
- Sotelo J, del Brutto OH, Penagos P, Escobedo F, Torres B, Rodriguez-Carbajal J, Rubio-Donnadieu F: Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis . J Neurol. 1990, 237:69-72. 10.1007/BF00314663
- Del Brutto OH: Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology. 1994, 44:1706-9. 10.1212/wnl.44.9.1706
- White AC Jr, Coyle CM, Rajshekhar V, et al.: Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018, 66:e49-75. 10.1093/cid/cix1084